A biotech company getting a patent is not exactly ground breaking. It proves nothing and it does not demonstrate efficacy or commerciality. And thus to "big it up" looks like a pre placing pimp. Especially...
Having failed to cure cancer, almost out of cash ValiRx (VAL) needs another story to ramp to allow its low-life brokers Peterhouse to get another discounted placing away to its spivvy flipper mates. Ahoy is that a bandwagon I see in the distance? Yes it is the Covid Express. Time to jump aboard.
Here we go again. Grace Slick could have been thinking of Peterhouse’s antics – as exposed here - when penning her most famous number “When logic and proportion, Have fallen sloppy dead” Exactly. So what is the ValiRx (VAL) white rabbit?
A bit of a storm has been blowing up at AIM-listed cash-hungry biotech dog ValiRx (VAL). A General Meeting had been proposed for shareholders to agree to the issue of yet more confetti in order to keep the Grim Reaper from the door but the government decreed Covid-19 lockdown intervened and the meeting could not happen. Yesterday the GM was reconvened with shareholders unable to attend or vote – and two of the three resolutions were passed. But what of legality?...
When I first commented on AIM-listed cancer drug developer ValiRx (VAL) back in 2016 the shares had just seen a pump’n’dump which pushed the stock up to 21p before a placing at just 12p. Now the stock is just 0.1p and on a market cap of £0.9m (source: ADVFN): never mind the 90% club, this is a fully paid up member of the 99% club. And now we have a placing for just £200,000 gross…..and Broker number three joins the fray, although as Tom Winnifrith points out the RNS will have to be reissued. How on earth can you justify paying three broker retainers for a company worth less than a million pounds?
I do not wish to be seen as a pedant but an RNS statement is meant to be, you know, like, er, accurate. And thus as an upstanding member of the AIM Casino community I have penned a quick email to my pal Liam Murray at Nomad Cairn Financial about today's RNS from ValirX (VAL) which appears to fail the accuracy test. I write.
Perhaps ValiRx (VAL) should be making a statement about events at Valiseek?
In this video from the storming success that was the 2017 UK Investor Show, Satu Vainikka of Valirx (VAL) is at the podium. And make sure that you keep April 21 2018 free for next year's UK Investor Show.
I was delighted to read this morning’s RNS from AIM-listed cancer-buster ValiRx (VAL): it has ditched the value-destroying funding package with Bracknor. About time too, this has been a disaster for the share price ever since it was announced back in March. With the shares having crashed from 12.5p the day before the package was announced to the current 6.875p (last seen) the damage has been horrific.
AIM-listed cancer-buster ValiRx (VAL) has its EGM today at 11.30am at the offices of DAC Beachcroft LLP, 100 Fetter Lane, London EC4AS 1BN. After shareholders voted to reject a resolution to disapply pre-emption rights at the AGM a couple of weeks back, the company has called a new gathering at which shareholders are being asked to vote on it again with management hoping that this time the shareholders get the answer right. Heck, it works for the EU, so why not here? Update - motion passed, shares down.
I highlighted yesterday that it seemed to me that the failure of shareholders in AIM-listed cancer-buster ValiRx to pass a special resolution at last week’s AGM to disapply pre-emption rights cast a bit of a shadow over the company’s funding arrangements. In a move straight out of the EU rulebook on democracy, shareholders are to be given the (ahem) opportunity to vote again in the hope of coming up with the right answer this time.
Shareholders in AIM-listed cancer-buster ValiRx (VAL) rejected a disapplication of pre-emption rights special resolution at the AGM held last Monday. The company said a further announcement would follow “in due course” but since then there has been silence. But it seems that there might be a few implications for the financing of the company going forward.
This morning saw AIM-listed ValiRx (VAL) appoint Beaufort Securities as Joint Broker. This coincided with a quarterly update RNS full of good news and Beaufort included a generous write-up in today’s morning note, with a “speculative buy” rating. All jolly good, but I fear that yet more errors have been made by the company.
